SCHEMBL26292124

SCHEMBL26292124

CCc1ccccc1-c1cc2ccc(OCO)cc2o1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 7/20 0.46
▸ NPC1 O15118 6/20 0.46
▸ ALDH1A1 P00352 3/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ KDM4E B2RXH2 3/20 0.43
▸ GLA P06280 3/20 0.43
▸ GAA P10253 2/20 0.43
▸ HPGD P15428 2/20 0.43
▸ RECQL P46063 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ CA12 O43570 4/20 0.42
▸ CA1 P00915 4/20 0.42
▸ CA9 Q16790 4/20 0.42
▸ CA6 P23280 3/20 0.42
▸ CA7 P43166 3/20 0.42
▸ CA14 Q9ULX7 3/20 0.42
▸ CA5B Q9Y2D0 3/20 0.42
▸ CA4 P22748 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24590436 0.90 CA12 (0.54) RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL30568041 0.87 MAOB (0.45) RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL20473365 0.87 MAOB (0.45) RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL30568050 0.85 PTPN1 (0.53) RAB9ANPC1ALDH1A1KDM4EGLA
SCHEMBL20473134 0.85 PTPN1 (0.53) RAB9ANPC1ALDH1A1KDM4EGLA
SCHEMBL22245951 0.83 SRD5A1 (0.40) RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL26291462 0.82 RAB9A (0.42) RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL26291461 0.82 RAB9A (0.40) RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL26292178 0.81 RAB9A (0.42) RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL21735365 0.81 S1PR1 (0.40) RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11753387-B2 Compounds for optically active devices Johnson & Johnson Surgical Vision, Inc. (US) 2023-09-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11753387-B2 Compounds for optically active devices PDE6C, PDE6A, PDE6D RAB9A 1119/4885NPC1 2727/4885ALDH1A1 388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback